PMID- 2909289
OWN - NLM
STAT- MEDLINE
DCOM- 19890209
LR  - 20190828
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 23
IP  - 1
DP  - 1989
TI  - Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in 
      P388 mouse lymphoma hybrid cells.
PG  - 41-6
AB  - Cultured P388/S mouse lymphoma cells resistant to 5-bromodeoxyuridine (BUdR) and 
      deficient in thymidine kinase (TK-) were fused with P388/DAG cells resistant to 
      1,2:5,6-dianhydrogalactitol (DAG), an anticancer alkylating agent, and to 
      6-thioguanine (6-TG) and deficient in hypoxanthine phosphoribosyl-transferase 
      (HPRT-). Sensitivity to DAG in the hybrid line was very close to that in the 
      P388/DAG line, which means that resistance to DAG was inherited in a 
      quasi-dominant manner. Hybrid cells showed cross-resistance, similar to that of 
      the DAG-resistant line, to two other hexitols, dibromodulcitol (DBD) and 
      disuccinyldianhydrogalactitol (DisuDAG).
FAU - Palyi, I
AU  - Palyi I
AD  - Research Institute of Oncopathology, National Institute of Oncology, Budapest, 
      Hungary.
FAU - Bence, J
AU  - Bence J
FAU - Szikla, K
AU  - Szikla K
FAU - Hullan, L
AU  - Hullan L
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Alkylating Agents)
RN  - 0 (Sugar Alcohols)
RN  - 4S465RYF7M (Dianhydrogalactitol)
RN  - EC 2.7.1.21 (Thymidine Kinase)
SB  - IM
MH  - Alkylating Agents/*pharmacology
MH  - Animals
MH  - Cell Survival/drug effects
MH  - Dianhydrogalactitol/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Hybrid Cells
MH  - Lymphoma/genetics/pathology
MH  - Mice
MH  - Mice, Inbred DBA
MH  - Sugar Alcohols/*pharmacology
MH  - Thymidine Kinase/analysis
MH  - Tumor Cells, Cultured/drug effects
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1007/BF00258456 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 1989;23(1):41-6. doi: 10.1007/BF00258456.